Viral impact on long-term kidney graft function

Infectious Disease Clinics of North America

Volumn 24, Issue 2, 2010, Pages 339-371

  Helanterä, Ilkka ^a   Egli, Adrian ^b,c   Koskinen, Petri ^a   Lautenschlager, Irmeli ^a   Hirsch, Hans H ^b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adenovirus; BK virus; Cytomegalovirus; HHV6; JC virus; Kidney transplantation; Parvovirus; Pathogenesis

Indexed keywords

CALCINEURIN INHIBITOR; CIDOFOVIR; CIDOFOVIR 3 HEXADECYLOXYPROPYL ESTER; CYCLOSPORIN; ERYTHROPOIETIN; GANCICLOVIR; IMMUNOGLOBULIN; LEFLUNOMIDE; MYCOPHENOLIC ACID; RIBAVIRIN; TACROLIMUS; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADENOVIRUS; ADENOVIRUS INFECTION; ANEMIA; ANTIVIRAL THERAPY; BK VIRUS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA VIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT SURVIVAL; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN PARVOVIRUS B19; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; JC VIRUS; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; NEPHROTOXICITY; PARVOVIRUS INFECTION; PATHOGENESIS; PATHOPHYSIOLOGY; POLYOMA VIRUS; REVIEW; RISK REDUCTION; VIRUS INFECTION; VIRUS REPLICATION;

HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; VIRUS DISEASES; VIRUSES;

EID: 77952757165     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.02.003     Document Type: Review

References (274)

1. Meier-Kriesche H.U., Li S., Gruessner R.W., et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006, 6(5 Pt 2):1111-1131.
2. Dharnidharka V.R., Stablein D.M., Harmon W.E. Post-transplant infections now exceed acute rejection as cause for hospitalization: a report of the NAPRTCS. Am J Transplant 2004, 4(3):384-389.
3. Dharnidharka V.R., Caillard S., Agodoa L.Y., et al. Infection frequency and profile in different age groups of kidney transplant recipients. Transplantation 2006, 81(12):1662-1667.
4. Fishman J.A. Infection in solid-organ transplant recipients. N Engl J Med 2007, 357(25):2601-2614.
5. Helantera I., Loginov R., Koskinen P., et al. Persistent cytomegalovirus infection is associated with increased expression of TGF-beta1, PDGF-AA and ICAM-1 and arterial intimal thickening in kidney allografts. Nephrol Dial Transplant 2005, 20(4):790-796.
6. Helantera I., Koskinen P., Finne P., et al. Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival. Transpl Int 2006, 19(11):893-900.
7. Humar A., Mazzulli T., Moussa G., et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005, 5(5):1065-1070.
8. Hirsch H.H., Knowles W., Dickenmann M., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002, 347(7):488-496.
9. Munoz P., Fogeda M., Bouza E., et al. Prevalence of BK virus replication among recipients of solid organ transplants. Clin Infect Dis 2005, 41(12):1720-1725.
10. Randhawa P., Uhrmacher J., Pasculle W., et al. A comparative study of BK and JC virus infections in organ transplant recipients. J Med Virol 2005, 77(2):238-243.
11. Egli A., Binggeli S., Bodaghi S., et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007, 22(Suppl 8):viii72-viii82.
12. Egli A., Infanti L., Dumoulin A., et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 2009, 199:837-846.
13. Fietze E., Prosch S., Reinke P., et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 1994, 58(6):675-680.
14. Reinke P., Prosch S., Kern F., et al. Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transpl Infect Dis 1999, 1(3):157-164.
15. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 1998, 338(24):1741-1751.
16. Sester M., Sester U., Gartner B., et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001, 71(9):1287-1294.
17. Comoli P., Azzi A., Maccario R., et al. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation 2004, 78(8):1229-1232.
18. Klenerman P., Hill A. T cells and viral persistence: lessons from diverse infections. Nat Immunol 2005, 6(9):873-879.
19. Comoli P., Hirsch H.H., Ginevri F. Cellular immune responses to BK virus. Curr Opin Organ Transplant 2008, 13(6):569-574.
20. Egli A., Binet I., Binggeli S., et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008, 6(1):29.
21. Lacey S.F., Gallez-Hawkins G., Crooks M., et al. Characterization of cytotoxic function of CMV-pp65-specific CD8+ T-lymphocytes identified by HLA tetramers in recipients and donors of stem-cell transplants. Transplantation 2002, 74(5):722-732.
22. Sester U., Gartner B.C., Wilkens H., et al. Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation. Am J Transplant 2005, 5(6):1483-1489.
23. Lacey S.F., La Rosa C., Zhou W., et al. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J Infect Dis 2006, 194(10):1410-1421.
24. Lilleri D., Zelini P., Fornara C., et al. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am J Transplant 2007, 7(8):1997-2005.
25. Egli A., Dumoulin A., Köhli S., et al. Polyomavirus BK after kidney transplantation - role of molecular and immunological markers. Trends in Transplantation 2009, 3:85-102.
26. Egli A., Koehli S., Dickenmann M., et al. Inhibition of polyomavirus BK- and cytomegalovirus-specific T-cell responses by immunosuppressive drugs. Transplantation 2009, 88(10):1161-1168.
27. Ginevri F., Azzi A., Hirsch H.H., et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007, 7(12):2727-2735.
28. Ginevri F., Basso S., Hirsch H.H., et al. Reconstitution of BKV-specific immunity through immunosuppression reduction prevents BKV nephropathy in pediatric kidney recipients monitored prospectively. Transpl Int 2007, 20. 80-80.
29. Preiksaitis J.K., Brennan D.C., Fishman J., et al. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005, 5(2):218-227.
30. Fishman J.A., Emery V., Freeman R., et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007, 21(2):149-158.
31. Hirsch H.H. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant 2002, 2(1):25-30.
32. Tantravahi J., Womer K.L., Kaplan B. Why hasn't eliminating acute rejection improved graft survival?. Annu Rev Med 2007, 58:369-385.
33. Kliem V., Fricke L., Wollbrink T., et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008, 8(5):975-983.
34. Brennan D.C. Cytomegalovirus in renal transplantation. J Am Soc Nephrol 2001, 12(4):848-855.
35. Schnitzler M.A., Lowell J.A., Hmiel S.P., et al. Cytomegalovirus disease after prophylaxis with oral ganciclovir in renal transplantation: the importance of HLA-DR matching. J Am Soc Nephrol 2003, 14(3):780-785.
36. Khoury J.A., Storch G.A., Bohl D.L., et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006, 6(9):2134-2143.
37. Gupta G., Gasper G., Bista B.R., et al. High production of TGF-beta increases the risk of development of BK virus allograft nephropathy [abstract 157]. Am J Transplant 2006, 6(S2):S119.
38. Gupta G., Ishwad C., Gasper G., et al. BK virus upregulates TGF-beta as well as specific components of the TGF-beta signaling pathway [abstract 158]. Am J Transplant 2006, 6(S2):S119-S120.
39. Abend J.R., Imperiale M.J. Transforming growth factor-beta-mediated regulation of BK virus gene expression. Virology 2008, 378(1):6-12.
40. Stewart P.L., Fuller S.D., Burnett R.M. Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J 1993, 12(7):2589-2599.
41. Leen A.M., Bollard C.M., Myers G.D., et al. Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12(3):243-251.
42. Roelvink P.W., Lizonova A., Lee J.G., et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998, 72(10):7909-7915.
43. Leen A.M., Rooney C.M. Adenovirus as an emerging pathogen in immunocompromised patients. Br J Haematol 2005, 128(2):135-144.
44. Bergelson J.M., Cunningham J.A., Droguett G., et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997, 275(5304):1320-1323.
45. Horvath J., Palkonyay L., Weber J. Group C adenovirus DNA sequences in human lymphoid cells. J Virol 1986, 59(1):189-192.
46. Chu Y., Sperber K., Mayer L., et al. Persistent infection of human adenovirus type 5 in human monocyte cell lines. Virology 1992, 188(2):793-800.
47. de Mezerville M.H., Tellier R., Richardson S., et al. Adenoviral infections in pediatric transplant recipients: a hospital-based study. Pediatr Infect Dis J 2006, 25(9):815-818.
48. Horwitz M.S. Adenovirus immunoregulatory genes and their cellular targets. Virology 2001, 279(1):1-8.
49. Ginsberg H.S., Moldawer L.L., Sehgal P.B., et al. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A 1991, 88(5):1651-1655.
50. Mistchenko A.S., Diez R.A., Mariani A.L., et al. Cytokines in adenoviral disease in children: association of interleukin-6, interleukin-8, and tumor necrosis factor alpha levels with clinical outcome. J Pediatr 1994, 124(5 Pt 1):714-720.
51. Myers G.D., Bollard C.M., Wu M.F., et al. Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantation. Bone Marrow Transplant 2007, 39(11):677-686.
52. Castle S.C. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000, 31(2):578-585.
53. Sester M., Sester U., Alarcon Salvador S., et al. Age-related decrease in adenovirus-specific T cell responses. J Infect Dis 2002, 185(10):1379-1387.
54. Mahr J.A., Gooding L.R. Immune evasion by adenoviruses. Immunol Rev 1999, 168:121-130.
55. Burgert H.G., Ruzsics Z., Obermeier S., et al. Subversion of host defense mechanisms by adenoviruses. Curr Top Microbiol Immunol 2002, 269:273-318.
56. Howard D.S., Phillips I.G., Reece D.E., et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 1999, 29(6):1494-1501.
57. Kojaoghlanian T., Flomenberg P., Horwitz M.S. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003, 13(3):155-171.
58. Yagisawa T., Nakada T., Takahashi K., et al. Acute hemorrhagic cystitis caused by adenovirus after kidney transplantation. Urol Int 1995, 54(3):142-146.
59. Cames B., Rahier J., Burtomboy G., et al. Acute adenovirus hepatitis in liver transplant recipients. J Pediatr 1992, 120(1):33-37.
60. Michaels M.G., Green M., Wald E.R., et al. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis 1992, 165(1):170-174.
61. Lecatsas G., van Wyk J.A. DNA viruses in urine after renal transplantation. S Afr Med J 1978, 53(20):787-788.
62. Humar A. Reactivation of viruses in solid organ transplant patients receiving cytomegalovirus prophylaxis. Transplantation 2006, 82(Suppl 2):S9-S14.
63. Hofland C.A., Eron L.J., Washecka R.M. Hemorrhagic adenovirus cystitis after renal transplantation. Transplant Proc 2004, 36(10):3025-3027.
64. Asim M., Chong-Lopez A., Nickeleit V. Adenovirus infection of a renal allograft. Am J Kidney Dis 2003, 41(3):696-701.
65. Hensley J.L., Sifri C.D., Cathro H.P., et al. Adenoviral graft-nephritis: case report and review of the literature. Transpl Int 2009, 22(6):672-677.
66. Ardehali H., Volmar K., Roberts C., et al. Fatal disseminated adenoviral infection in a renal transplant patient. Transplantation 2001, 71(7):998-999.
67. Wreghitt T.G., Gray J.J., Ward K.N., et al. Disseminated adenovirus infection after liver transplantation and its possible treatment with ganciclovir. J Infect 1989, 19(1):88-89.
68. Murphy G.F., Wood D.P., McRoberts J.W., et al. Adenovirus-associated hemorrhagic cystitis treated with intravenous ribavirin. J Urol 1993, 149(3):565-566.
69. Arav Boger R., Echavarria M., Forman M., et al. Clearance of adenoviral hepatitis with ribavirin therapy in a pediatric liver transplant recipient. Pediatr Infect Dis J 2000, 19(11):1097-1100.
70. Swaminathan S., Lager D.J., Qian X., et al. Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 2006, 21(9):2607-2614.
71. Thomas L.D., Milstone A.P., Vilchez R.A., et al. Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation. Transplantation 2009, 88(3):360-366.
72. Elphick G.F., Querbes W., Jordan J.A., et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004, 306(5700):1380-1383.
73. Low J.A., Magnuson B., Tsai B., et al. Identification of gangliosides GD1b and GT1b as receptors for BK virus. J Virol 2006, 80(3):1361-1366.
74. Bialasiewicz S., Whiley D.M., Lambert S.B., et al. A newly reported human polyomavirus, KI virus, is present in the respiratory tract of Australian children. J Clin Virol 2007, 40(1):15-18.
75. Dalianis T., Ramqvist T., Andreasson K., et al. KI, WU and Merkel cell polyomaviruses: a new era for human polyomavirus research. Semin Cancer Biol 2009, 19(4):270-275.
76. Sharp C.P., Norja P., Anthony I., et al. Reactivation and mutation of newly discovered WU, KI, and Merkel cell carcinoma polyomaviruses in immunosuppressed individuals. J Infect Dis 2009, 199(3):398-404.
77. Wieland U., Mauch C., Kreuter A., et al. Merkel cell polyomavirus DNA in persons without Merkel cell carcinoma. Emerg Infect Dis 2009, 15:1496-1498.
78. Mourez T., Bergeron A., Ribaud P., et al. Polyomaviruses KI and WU in immunocompromised patients with respiratory disease. Emerg Infect Dis 2009, 15(1):107-109.
79. Babakir-Mina M., Ciccozzi M., Alteri C., et al. Excretion of the novel polyomaviruses KI and WU in the stool of patients with hematological disorders. J Med Virol 2009, 81(9):1668-1673.
80. Knowles W.A., Pipkin P., Andrews N., et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003, 71(1):115-123.
81. Kean J.M., Rao S., Wang M., et al. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009, 5(3):e1000363.
82. Knowles W.A. Propagation and assay of BK virus. Methods Mol Biol 2001, 165:19-31.
83. Ginevri F., De Santis R., Comoli P., et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003, 75(8):1266-1270.
84. Chen Y., Trofe J., Gordon J., et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 2006, 80(7):3495-3505.
85. Leuenberger D., Andresen P.A., Gosert R., et al. Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. Clin Vaccine Immunol 2007, 14(8):959-968.
86. Randhawa P.S., Gupta G., Vats A., et al. Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol 2006, 13(9):1057-1063.
87. Bohl D.L., Storch G.A., Ryschkewitsch C., et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005, 5(9):2213-2221.
88. Ramos E., Drachenberg C.B., Papadimitriou J.C., et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002, 13(8):2145-2151.
89. Smith J.M., McDonald R.A., Finn L.S., et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004, 4(12):2109-2117.
90. Binet I., Nickeleit V., Hirsch H.H., et al. Polyomavirus disease under new immunosuppressive drugs: a cause of renal graft dysfunction and graft loss. Transplantation 1999, 67(6):918-922.
91. Mengel M., Marwedel M., Radermacher J., et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003, 18(6):1190-1196.
92. Brennan D.C., Agha I., Bohl D.L., et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005, 5(3):582-594.
93. Hirsch H.H., Friman S., Wiecek A., et al. Prospective study of polyomavirus BK viruria and viremia in de novo renal transplantation [abstract 77]. Am J Transplant 2007, 7(Suppl 5):150.
94. Dharnidharka V.R., Cherikh W.S., Abbott K.C. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009, 87(7):1019-1026.
95. Manitpisitkul W., Drachenberg C., Ramos E., et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: a case-control study. Transplantation 2009, 88(1):83-88.
96. Awadallah Y., Randhawa P., Ruppert K., et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 2004, 4(10):1691-1696.
97. Kayler L.K., Batal I., Mohanka R., et al. Antirejection treatment in kidney transplant patients with BK viruria. Transplantation 2008, 86(6):797-803.
98. Comoli P., Basso S., Azzi A., et al. Dendritic cells pulsed with polyomavirus BK antigen induce ex vivo polyoma BK virus-specific cytotoxic T-cell lines in seropositive healthy individuals and renal transplant recipients. J Am Soc Nephrol 2003, 14(12):3197-3204.
99. Binggeli S., Egli A., Dickenmann M., et al. BKV replication and cellular immune responses in renal transplant recipients. Am J Transplant 2006, 6(9):2218-2219.
100. Comoli P., Azzi A., Basso S., et al. Prospective evaluation of BKV-specific cellular immunity after pediatric kidney transplantation [abstract 79]. Am J Transplant 2006, 6(S2):S93.
101. Prosser S.E., Orentas R.J., Cohen E.P., et al. Elispot as a technique for measuring BKV-specific cellular immunity in clinical BKV nephritis [abstract 1859]. Am J Transplant 2006, 6(S2):S685.
102. Binggeli S., Egli A., Schaub S., et al. Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 2007, 7(5):1131-1139.
103. Hammer M.H., Brestrich G., Andree H., et al. HLA type-independent method to monitor polyoma BK virus-specific CD4 and CD8 T-cell immunity. Am J Transplant 2006, 6(3):625-631.
104. Schaub S., Mayr M., Egli A., et al. Transient allograft dysfunction from immune reconstitution in a patient with polyoma BK-virus-associated nephropathy. Nephrol Dial Transplant 2007, 22(8):2386-2390.
105. Stolt A., Sasnauskas K., Koskela P., et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003, 84(Pt 6):1499-1504.
106. Gosert R., Rinaldo C.H., Funk G.A., et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008, 205(4):841-852.
107. Chesters P.M., Heritage J., McCance D.J. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis 1983, 147(4):676-684.
108. Dorries K., ter Meulen V. Progressive multifocal leucoencephalopathy: detection of papovavirus JC in kidney tissue. J Med Virol 1983, 11(4):307-317.
109. Polo C., Perez J.L., Mielnichuck A., et al. Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children. Clin Microbiol Infect 2004, 10(7):640-644.
110. Zhong S., Zheng H.Y., Suzuki M., et al. Age-related urinary excretion of BK polyomavirus by nonimmunocompromised individuals. J Clin Microbiol 2007, 45(1):193-198.
111. Ling P.D., Lednicky J.A., Keitel W.A., et al. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis 2003, 187(10):1571-1580.
112. Drachenberg C.B., Hirsch H.H., Papadimitriou J.C., et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation 2007, 84(3):323-330.
113. Funk G.A., Gosert R., Comoli P., et al. Polyomavirus BK replication dynamics in vivo and in silico to predict cytopathology and viral clearance in kidney transplants. Am J Transplant 2008, 8:2368-2377.
114. Nickeleit V., Klimkait T., Binet I.F., et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000, 342(18):1309-1315.
115. Hirsch H.H., Drachenberg C.B., Steiger J., et al. Polyomavirus-associated nephropathy in renal transplantation: critical issues of screening and management. Adv Exp Med Biol 2006, 577:160-173.
116. Hirsch H.H., Drachenberg C., Ramos E., et al. BK viremia level strongly correlates with the extent/pattern of viral nephropathy (BKPVN) implications for a diagnostic cut-off value [abstract 1168]. Transplantation 2006, 82(1):460.
117. Viscount H.B., Eid A.J., Espy M.J., et al. Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation 2007, 84(3):340-345.
118. Drachenberg C.B., Hirsch H.H., Ramos E., et al. Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. Hum Pathol 2005, 36(12):1245-1255.
119. Hirsch H.H., Brennan D.C., Drachenberg C.B., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005, 79(10):1277-1286.
120. Drachenberg C.B., Papadimitriou J.C., Hirsch H.H., et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004, 4(12):2082-2092.
121. Drachenberg C.B., Papadimitriou J.C., Ramos E., et al. Histologic versus molecular diagnosis of BK polyomavirus-associated nephropathy: a shifting paradigm?. Clin J Am Soc Nephrol 2006, 1(3):374-379.
122. Drachenberg C.B., Papadimitriou J.C. Polyomavirus-associated nephropathy: update in diagnosis. Transpl Infect Dis 2006, 8(2):68-75.
123. Grinde B., Gayorfar M., Rinaldo C.H. Impact of a polyomavirus (BKV) infection on mRNA expression in human endothelial cells. Virus Res 2007, 123(1):86-94.
124. Cheng O., Abend J.R., Imperiale J., et al. The pro-fibriogenic effect of BK polyomavirus infection [abstract 81]. Am J Transplant 2006, 6(S2):S93-S94.
125. Sporn M.B. The early history of TGF-beta, and a brief glimpse of its future. Cytokine Growth Factor Rev 2006, 17(1-2):3-7.
126. Mannon R.B., Hoffmann S.C., Kampen R.L., et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant 2005, 5(12):2883-2893.
127. Rinaldo C.H., Hirsch H.H. Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti Infect Ther 2007, 5(1):105-115.
128. Trofe J., Hirsch H.H., Ramos E. Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis 2006, 8(2):76-85.
129. Farasati N.A., Shapiro R., Vats A., et al. Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 2005, 79(1):116-118.
130. Randhawa P., Farasati N.A., Shapiro R., et al. Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro. Antimicrob Agents Chemother 2006, 50(4):1564-1566.
131. Bernhoff E., Gutteberg T.J., Sandvik K., et al. Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 2008, 8:1413-1422.
132. Williams J.W., Javaid B., Kadambi P.V., et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 2005, 352(11):1157-1158.
133. Josephson M.A., Williams J.W., Chandraker A., et al. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis 2006, 8(2):95-101.
134. Faguer S., Hirsch H.H., Kamar N., et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007, 20(11):962-969.
135. Baumann P., Mandl-Weber S., Volkl A., et al. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells. Mol Cancer Ther 2009, 8(2):366-375.
136. Rinaldo CH, Gosert R, Hirsch HH. Hexadecyloxypropyl-cidofovir (CMX001) BK virus (BKV) replication in primary renal tubular epithelial cells [abstract OP5-8]. J Clin Virol 2009;46(Suppl 1):S12-3.
137. Dunn W., Chou C., Li H., et al. Functional profiling of a human cytomegalovirus genome. Proc Natl Acad Sci U S A 2003, 100(24):14223-14228.
138. Dolan A., Cunningham C., Hector R.D., et al. Genetic content of wild-type human cytomegalovirus. J Gen Virol 2004, 85(Pt 5):1301-1312.
139. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990, 12(Suppl 7):S701-S710.
140. Becker B.N., Becker Y.T., Leverson G.E., et al. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation. Am J Kidney Dis 2002, 39(5):1088-1095.
141. Sagedal S., Nordal K.P., Hartmann A., et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002, 2(9):850-856.
142. Sagedal S., Nordal K.P., Hartmann A., et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000, 70(8):1166-1174.
143. Rubin R.H., Tolkoff-Rubin N.E. Viral infection in the renal transplant patient. Proc Eur Dial Transplant Assoc 1983, 19:513-526.
144. von Willebrand E., Pettersson E., Ahonen J., et al. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 1986, 42(4):364-367.
145. Pouteil-Noble C., Ecochard R., Landrivon G., et al. Cytomegalovirus infection-an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 1993, 55(4):851-857.
146. Reinke P., Fietze E., Ode-Hakim S., et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994, 344(8939-8940):1737-1738.
147. Toupance O., Bouedjoro-Camus M.C., Carquin J., et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transpl Int 2000, 13(6):413-419.
148. Dickenmann M.J., Cathomas G., Steiger J., et al. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001, 71(6):764-767.
149. Reischig T., Jindra P., Svecova M., et al. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection. J Clin Virol 2006, 36(2):146-151.
150. Reischig T., Jindra P., Hes O., et al. Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis. Transplantation 2009, 87(3):436-444.
151. Richardson W.P., Colvin R.B., Cheeseman S.H., et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1981, 305(2):57-63.
152. Tuazon T.V., Schneeberger E.E., Bhan A.K., et al. Mononuclear cells in acute allograft glomerulopathy. Am J Pathol 1987, 129(1):119-132.
153. Rao K.V., Hafner G.P., Crary G.S., et al. De novo immunotactoid glomerulopathy of the renal allograft: possible association with cytomegalovirus infection. Am J Kidney Dis 1994, 24(1):97-103.
154. Fryd D.S., Peterson P.K., Ferguson R.M., et al. Cytomegalovirus as a risk factor in renal transplantation. Transplantation 1980, 30(6):436-439.
155. Rubin R.H., Tolkoff-Rubin N.E., Oliver D., et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 1985, 40(3):243-249.
156. Lewis R.M., Johnson P.C., Golden D., et al. The adverse impact of cytomegalovirus infection on clinical outcome in cyclosporine-prednisone treated renal allograft recipients. Transplantation 1988, 45(2):353-359.
157. Tong C.Y., Bakran A., Peiris J.S., et al. The association of viral infection and chronic allograft nephropathy with graft dysfunction after renal transplantation. Transplantation 2002, 74(4):576-578.
158. Geddes C.C., Church C.C., Collidge T., et al. Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. Nephrol Dial Transplant 2003, 18(9):1891-1898.
159. Sola R., Diaz J.M., Guirado L., et al. Significance of cytomegalovirus infection in renal transplantation. Transplant Proc 2003, 35(5):1753-1755.
160. Opelz G., Dohler B., Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4(6):928-936.
161. Sagedal S., Hartmann A., Nordal K.P., et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004, 66(1):329-337.
162. Arthurs S.K., Eid A.J., Pedersen R.A., et al. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008, 46(6):840-846.
163. Akposso K., Rondeau E., Haymann J.P., et al. Long-term prognosis of renal transplantation after preemptive treatment of cytomegalovirus infection. Transplantation 1997, 63(7):974-976.
164. Ricart M.J., Malaise J., Moreno A., et al. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation. Nephrol Dial Transplant 2005, 20(Suppl 2):ii25-ii32. ii62.
165. Grattan M.T., Moreno-Cabral C.E., Starnes V.A., et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261(24):3561-3566.
166. Loebe M., Schuler S., Zais O., et al. Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant 1990, 9(6):707-711.
167. Arnold J.C., Portmann B.C., O'Grady J.G., et al. Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome. Hepatology 1992, 16(2):285-292.
168. Koskinen P.K., Nieminen M.S., Krogerus L.A., et al. Cytomegalovirus infection and accelerated cardiac allograft vasculopathy in human cardiac allografts. J Heart Lung Transplant 1993, 12(5):724-729.
169. Kroshus T.J., Kshettry V.R., Savik K., et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997, 114(2):195-202.
170. Lautenschlager I., Hockerstedt K., Jalanko H., et al. Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 1997, 25(1):190-194.
171. Evans P.C., Coleman N., Wreghitt T.G., et al. Cytomegalovirus infection of bile duct epithelial cells, hepatic artery and portal venous endothelium in relation to chronic rejection of liver grafts. J Hepatol 1999, 31(5):913-920.
172. Valantine H.A., Gao S.Z., Menon S.G., et al. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 1999, 100(1):61-66.
173. Solez K., Colvin R.B., Racusen L.C., et al. Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007, 7(3):518-526.
174. Humar A., Gillingham K.J., Payne W.D., et al. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999, 68(12):1879-1883.
175. Helantera I., Koskinen P., Tornroth T., et al. The impact of cytomegalovirus infections and acute rejection episodes on the development of vascular changes in 6-month protocol biopsy specimens of cadaveric kidney allograft recipients. Transplantation 2003, 75(11):1858-1864.
176. Heieren M.H., Kim Y.K., Balfour H.H. Human cytomegalovirus infection of kidney glomerular visceral epithelial and tubular epithelial cells in culture. Transplantation 1988, 46(3):426-432.
177. Heieren M.H., van der Woude F.J., Balfour H.H. Cytomegalovirus replicates efficiently in human kidney mesangial cells. Proc Natl Acad Sci U S A 1988, 85(5):1642-1646.
178. Ustinov J.A., Loginov R.J., Mattila P.M., et al. Cytomegalovirus infection of human kidney cells in vitro. Kidney Int 1991, 40(5):954-960.
179. Ulrich W., Schlederer M.P., Buxbaum P., et al. The histopathologic identification of CMV infected cells in biopsies of human renal allografts. An evaluation of 100 transplant biopsies by in situ hybridization. Pathol Res Pract 1986, 181(6):739-745.
180. Andersen C.B., Ladefoged S.D., Lauritsen H.K., et al. Detection of CMV DNA and CMV antigen in renal allograft biopsies by in situ hybridisation and immunohistochemistry. Nephrol Dial Transplant 1990, 5(12):1045-1050.
181. Lardelli P., Aguilar D., Gomez-Morales M., et al. Presence of cytomegalovirus genome and leucocyte subsets in renal transplant biopsies. Relationship with prognosis. Pathol Res Pract 1994, 190(2):142-150.
182. Holma K., Tornroth T., Gronhagen-Riska C., et al. Expression of the cytomegalovirus genome in kidney allografts during active and latent
183. Liapis H., Storch G.A., Hill D.A., et al. CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. Nephrol Dial Transplant 2003, 18(2):397-402.
184. Iwamoto G.K., Monick M.M., Clark B.D., et al. Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus. J Clin Invest 1990, 85(6):1853-1857.
185. Geist L.J., Monick M.M., Stinski M.F., et al. The immediate early genes of human cytomegalovirus upregulate expression of the interleukin-2 and interleukin-2 receptor genes. Am J Respir Cell Mol Biol 1991, 5(3):292-296.
186. Smith P.D., Saini S.S., Raffeld M., et al. Cytomegalovirus induction of tumor necrosis factor-alpha by human monocytes and mucosal macrophages. J Clin Invest 1992, 90(5):1642-1648.
187. van Dorp W.T., van Wieringen P.A., Marselis-Jonges E., et al. Cytomegalovirus directly enhances MHC class I and intercellular adhesion molecule-1 expression on cultured proximal tubular epithelial cells. Transplantation 1993, 55(6):1367-1371.
188. Sedmak D.D., Knight D.A., Vook N.C., et al. Divergent patterns of ELAM-1, ICAM-1, and VCAM-1 expression on cytomegalovirus-infected endothelial cells. Transplantation 1994, 58(12):1379-1385.
189. Craigen J.L., Grundy J.E. Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation 1996, 62(8):1102-1108.
190. Srivastava R., Curtis M., Hendrickson S., et al. Strain specific effects of cytomegalovirus on endothelial cells: implications for investigating the relationship between CMV and cardiac allograft vasculopathy. Transplantation 1999, 68(10):1568-1573.
191. Reinhardt B., Mertens T., Mayr-Beyrle U., et al. HCMV infection of human vascular smooth muscle cells leads to enhanced expression of functionally intact PDGF beta-receptor. Cardiovasc Res 2005, 67(1):151-160.
192. Reinhardt B., Schaarschmidt P., Bossert A., et al. Upregulation of functionally active vascular endothelial growth factor by human cytomegalovirus. J Gen Virol 2005, 86(Pt 1):23-30.
193. Yilmaz S., Koskinen P.K., Kallio E., et al. Cytomegalovirus infection-enhanced chronic kidney allograft rejection is linked with intercellular adhesion molecule-1 expression. Kidney Int 1996, 50(2):526-537.
194. Lautenschlager I., Soots A., Krogerus L., et al. Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat. Transplantation 1997, 64(3):391-398.
195. van Dam J.G., Damoiseaux J.G., Christiaans M.H., et al. Acute primary infection with cytomegalovirus (CMV) in kidney transplant recipients results in the appearance of a phenotypically aberrant CD8+ T cell population. Microbiol Immunol 2000, 44(12):1011-1017.
196. Inkinen K., Soots A., Krogerus L., et al. Cytomegalovirus increases collagen synthesis in chronic rejection in the rat. Nephrol Dial Transplant 2002, 17(5):772-779.
197. Kloover J.S., Soots A.P., Krogerus L.A., et al. Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1 vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 2000, 69(12):2641-2647.
198. Phan S.H., Gharaee-Kermani M., McGarry B., et al. Regulation of rat pulmonary artery endothelial cell transforming growth factor-beta production by IL-1 beta and tumor necrosis factor-alpha. J Immunol 1992, 149(1):103-106.
199. Pintavorn P., Ballermann B.J. TGF-beta and the endothelium during immune injury. Kidney Int 1997, 51(5):1401-1412.
200. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev 1997, 8(3):171-179.
201. Michelson S., Alcami J., Kim S.J., et al. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J Virol 1994, 68(9):5730-5737.
202. Yoo Y.D., Chiou C.J., Choi K.S., et al. The IE2 regulatory protein of human cytomegalovirus induces expression of the human transforming growth factor beta1 gene through an Egr-1 binding site. J Virol 1996, 70(10):7062-7070.
203. Funayama H., Ikeda U., Takahashi M., et al. Human monocyte-endothelial cell interaction induces platelet-derived growth factor expression. Cardiovasc Res 1998, 37(1):216-224.
204. Isoniemi H., Taskinen E., Hayry P. Histological chronic allograft damage index accurately predicts chronic renal allograft rejection. Transplantation 1994, 58(11):1195-1198.
205. Krogerus L., Soots A., Loginov R., et al. CMV increases tubular apoptosis through the TNF-alpha-TNF-R1 pathway in a rat model of chronic renal allograft rejection. Transpl Immunol 2008, 18(3):232-236.
206. Penfold M.E., Dairaghi D.J., Duke G.M., et al. Cytomegalovirus encodes a potent alpha chemokine. Proc Natl Acad Sci U S A 1999, 96(17):9839-9844.
207. Vink C., Beisser P.S., Bruggeman C.A. Molecular mimicry by cytomegaloviruses. Function of cytomegalovirus-encoded homologues of G protein-coupled receptors, MHC class I heavy chains and chemokines. Intervirology 1999, 42(5-6):342-349.
208. Streblow D.N., Vomaske J., Smith P., et al. Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinase and Src. J Biol Chem 2003, 278(50):50456-50465.
209. Streblow D.N., Kreklywich C.N., Smith P., et al. Rat cytomegalovirus-accelerated transplant vascular sclerosis is reduced with mutation of the chemokine-receptor R33. Am J Transplant 2005, 5(3):436-442.
210. Streblow D.N., Kreklywich C.N., Andoh T., et al. The role of angiogenic and wound repair factors during CMV-accelerated transplant vascular sclerosis in rat cardiac transplants. Am J Transplant 2008, 8(2):277-287.
211. Dumortier J., Streblow D.N., Moses A.V., et al. Human cytomegalovirus secretome contains factors that induce angiogenesis and wound healing. J Virol 2008, 82(13):6524-6535.
212. Cook C.H., Bickerstaff A.A., Wang J.J., et al. Disruption of murine cardiac allograft acceptance by latent cytomegalovirus. Am J Transplant 2009, 9(1):42-53.
213. Moens U., Van Ghelue M., Bendiksen S., et al. Simian virus 40 large T-antigen, but not small T-antigen, trans-activates the human cytomegalovirus major immediate early promoter. Virus Genes 2001, 23(2):215-226.
214. Toyoda M., Puliyanda D.P., Amet N., et al. Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients. Transplantation 2005, 80(2):198-205.
215. Biberfeld P., Kramarsky B., Salahuddin S.Z., et al. Ultrastructural characterization of a new human B lymphotropic DNA virus (human herpesvirus 6) isolated from patients with lymphoproliferative disease. J Natl Cancer Inst 1987, 79(5):933-941.
216. Dominguez G., Dambaugh T.R., Stamey F.R., et al. Human herpesvirus 6B genome sequence: coding content and comparison with human herpesvirus 6A. J Virol 1999, 73(10):8040-8052.
217. Efstathiou S., Gompels U.A., Craxton M.A., et al. DNA homology between a novel human herpesvirus (HHV-6) and human cytomegalovirus. Lancet 1988, 1(8575-6):63-64.
218. De Bolle L., Naesens L., De Clercq E. Update on human herpesvirus 6 biology, clinical features, and therapy. Clin Microbiol Rev 2005, 18(1):217-245.
219. Frenkel N., Schirmer E.C., Wyatt L.S., et al. Isolation of a new herpesvirus from human CD4+ T cells. Proc Natl Acad Sci U S A 1990, 87(2):748-752.
220. Dominguez G., Black J.B., Stamey F.R., et al. Physical and genetic maps of the human herpesvirus 7 strain SB genome. Arch Virol 1996, 141(12):2387-2408.
221. Lusso P., Secchiero P., Crowley R.W., et al. CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus. Proc Natl Acad Sci U S A 1994, 91(9):3872-3876.
222. Santoro F., Kennedy P.E., Locatelli G., et al. CD46 is a cellular receptor for human herpesvirus 6. Cell 1999, 99(7):817-827.
223. Yamanishi K., Okuno T., Shiraki K., et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988, 1(8594):1065-1067.
224. Tanaka K., Kondo T., Torigoe S., et al. Human herpesvirus 7: another causal agent for roseola (exanthem subitum). J Pediatr 1994, 125(1):1-5.
225. Hashida T., Komura E., Yoshida M., et al. Hepatitis in association with human herpesvirus-7 infection. Pediatrics 1995, 96(4 Pt 1):783-785.
226. Ward K.N. The natural history and laboratory diagnosis of human herpesviruses-6 and -7 infections in the immunocompetent. J Clin Virol 2005, 32(3):183-193.
227. Griffiths P.D., Ait-Khaled M., Bearcroft C.P., et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. J Med Virol 1999, 59(4):496-501.
228. Ljungman P., Singh N. Human herpesvirus-6 infection in solid organ and stem cell transplant recipients. J Clin Virol 2006, 37(Suppl 1):S87-S91.
229. Smith J.M., McDonald R.A. Emerging viral infections in transplantation. Pediatr Transplant 2006, 10:1-6.
230. Ward K.N., Gray J.J., Efstathiou S. Brief report: primary human herpesvirus 6 infection in a patient following liver transplantation from a seropositive donor. J Med Virol 1989, 28(2):69-72.
231. Herbein G., Strasswimmer J., Altieri M., et al. Longitudinal study of human herpesvirus 6 infection in organ transplant recipients. Clin Infect Dis 1996, 22(1):171-173.
232. Singh N., Carrigan D.R., Gayowski T., et al. Human herpesvirus-6 infection in liver transplant recipients: documentation of pathogenicity. Transplantation 1997, 64(5):674-678.
233. Lautenschlager I., Hockerstedt K., Linnavuori K., et al. Human herpesvirus-6 infection after liver transplantation. Clin Infect Dis 1998, 26(3):702-707.
234. Humar A., Kumar D., Raboud J., et al. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002, 2(5):461-466.
235. Razonable R.R., Paya C.V. The impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation. Liver Transpl 2002, 8(8):651-658.
236. Halme L., Arola J., Hockerstedt K., et al. Human herpesvirus 6 infection of the gastroduodenal mucosa. Clin Infect Dis 2008, 46(3):434-439.
237. Flamand L., Gosselin J., D'Addario M., et al. Human herpesvirus 6 induces interleukin-1 beta and tumor necrosis factor alpha, but not interleukin-6, in peripheral blood mononuclear cell cultures. J Virol 1991, 65(9):5105-5110.
238. Lautenschlager I., Harma M., Hockerstedt K., et al. Human herpesvirus-6 infection is associated with adhesion molecule induction and lymphocyte infiltration in liver allografts. J Hepatol 2002, 37(5):648-654.
239. Morris D.J., Littler E., Arrand J.R., et al. Human herpesvirus 6 infection in renal-transplant recipients. N Engl J Med 1989, 320(23):1560-1561.
240. Okuno T., Higashi K., Shiraki K., et al. Human herpesvirus 6 infection in renal transplantation. Transplantation 1990, 49(3):519-522.
241. Hoshino K., Nishi T., Adachi H., et al. Human herpesvirus-6 infection in renal allografts: retrospective immunohistochemical study in Japanese recipients. Transpl Int 1995, 8(3):169-173.
242. Sebekova K., Feber J., Carpenter B., et al. Tissue viral DNA is associated with chronic allograft nephropathy. Pediatr Transplant 2005, 9(5):598-603.
243. Helantera I., Loginov R., Koskinen P., et al. Demonstration of HHV-6 antigens in biopsies of kidney transplant recipients with cytomegalovirus infection. Transpl Int 2008, 21(10):980-984.
244. Kidd I.M., Clark D.A., Sabin C.A., et al. Prospective study of human betaherpesviruses after renal transplantation: association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 2000, 69(11):2400-2404.
245. Osman H.K., Peiris J.S., Taylor C.E., et al. Cytomegalovirus disease in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression?. J Med Virol 1996, 48(4):295-301.
246. Brown K.E., Anderson S.M., Young N.S., et al. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 1993, 262(5130):114-117.
247. Brown K.E., Hibbs J.R., Gallinella G., et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). N Engl J Med 1994, 330(17):1192-1196.
248. Anderson L.J. Human parvovirus B19. Pediatr Ann 1990, 19(9):509-510. 512-3.
249. Anderson L.J. Human parvoviruses. J Infect Dis 1990, 161(4):603-608.
250. Lindner J., Barabas S., Saar K., et al. CD4(+) T-cell responses against the VP1-unique region in individuals with recent and persistent parvovirus B19 infection. J Vet Med B Infect Dis Vet Public Health 2005, 52(7-8):356-361.
251. Ogata M., Satou T., Kawano R., et al. Plasma HHV-6 viral load-guided preemptive therapy against HHV-6 encephalopathy after allogeneic stem cell transplantation: a prospective evaluation. Bone Marrow Transplant 2008, 41(3):279-285.
252. Norbeck O., Isa A., Pohlmann C., et al. Sustained CD8+ T-cell responses induced after acute parvovirus B19 infection in humans. J Virol 2005, 79(18):12117-12121.
253. Isa A., Norbeck O., Hirbod T., et al. Aberrant cellular immune responses in humans infected persistently with parvovirus B19. J Med Virol 2006, 78(1):129-133.
254. Kerr J.R., Cunniffe V.S., Kelleher P., et al. Circulating cytokines and chemokines in acute symptomatic parvovirus B19 infection: negative association between levels of pro-inflammatory cytokines and development of B19-associated arthritis. J Med Virol 2004, 74(1):147-155.
255. Kerr J.R. Pathogenesis of parvovirus B19 infection: host gene variability, and possible means and effects of virus persistence. J Vet Med B Infect Dis Vet Public Health 2005, 52(7-8):335-339.
256. Kelly H., Leydon J. Letter to the editor: outbreaks caused by parvovirus B19. Euro Surveill 2005, 10(9):E1-E2. [author reply: E5-6].
257. Azzi A., Morfini M., Mannucci P.M. The transfusion-associated transmission of parvovirus B19. Transfus Med Rev 1999, 13(3):194-204.
258. Heegaard E.D., Laub Petersen B. Parvovirus B19 transmitted by bone marrow. Br J Haematol 2000, 111(2):659-661.
259. Broliden K. Parvovirus B19 infection in pediatric solid-organ and bone marrow transplantation. Pediatr Transplant 2001, 5(5):320-330.
260. Murer L., Zacchello G., Bianchi D., et al. Thrombotic microangiopathy associated with parvovirus B 19 infection after renal transplantation. J Am Soc Nephrol 2000, 11(6):1132-1137.
261. Moudgil A., Nast C.C., Bagga A., et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 2001, 59(6):2126-2133.
262. Iwafuchi Y., Morita T., Kamimura A. Acute endocapillary proliferative glomerulonephritis associated with human parvovirus B19 infection. Clin Nephrol 2002, 57(3):246-250.
263. Onguru P., Dede F., Bodur H., et al. Glomerulonephritis associating parvovirus B19 infection. Ren Fail 2006, 28(1):85-88.
264. Cossart Y.E., Field A.M., Cant B., et al. Parvovirus-like particles in human sera. Lancet 1975, 1(7898):72-73.
265. Neild G., Anderson M., Hawes S., et al. Parvovirus infection after renal transplant. Lancet 1986, 2(8517):1226-1227.
266. Laurenz M., Winkelmann B., Roigas J., et al. Severe parvovirus B19 encephalitis after renal transplantation. Pediatr Transplant 2006, 10(8):978-981.
267. Rodrigues C., Pinto D., Medeiros R. Molecular epidemiology characterization of the urinary excretion of polyomavirus in healthy individuals from Portugal-a Southern European population. J Med Virol 2007, 79(8):1194-1198.
268. Ki C.S., Kim I.S., Kim J.W., et al. Incidence and clinical significance of human parvovirus B19 infection in kidney transplant recipients. Clin Transplant 2005, 19(6):751-755.
269. Eid A.J., Brown R.A., Patel R., et al. Parvovirus B19 infection after transplantation: a review of 98 cases. Clin Infect Dis 2006, 43(1):40-48.
270. Cavallo R., Merlino C., Re D., et al. B19 virus infection in renal transplant recipients. J Clin Virol 2003, 26(3):361-368.
271. Park J.B., Kim D.J., Woo S.Y., et al. Clinical implications of quantitative real time-polymerase chain reaction of parvovirus B19 in kidney transplant recipients - a prospective study. Transpl Int 2009, 22(4):455-462.
272. Ardalan M.R., Shoja M.M., Tubbs R.S., et al. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus b19 infection. Am J Transplant 2008, 8(6):1340-1344.
273. Moudgil A., Shidban H., Nast C.C., et al. Parvovirus B19 infection-related complications in renal transplant recipients: treatment with intravenous immunoglobulin. Transplantation 1997, 64(12):1847-1850.
274. Beckhoff A., Steffen I., Sandoz P., et al. Relapsing severe anaemia due to primary parvovirus B19 infection after renal transplantation: a case report and review of the literature. Nephrol Dial Transplant 2007, 22(12):3660-3663.